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Forty clonally related clinical isolates of Escherichia coli from hospitalized patients were resistant to cefoxitin
(MICs, >256 mg/ml) and ceftazidime (MICs, 32 to 256 mg/ml) and were intermediate or resistant to cefotaxime
(MICs, 16 to 128 mg/ml) but susceptible to both cefepime (MICs, 0.5 to 2 mg/ml) and imipenem (MICs, 0.125
to 0.25 mg/ml). Resistance to b-lactams was related to high-level production of AmpC b-lactamase and loss of
OmpF porin.
Most Escherichia coli strains do not produce clinically rele-
vant levels of the chromosomally encoded AmpC b-lactamase
(4). Gene amplification or mutations at either the promoter
and/or the attenuator of the structural b-lactamase gene result
in AmpC hyperproduction (2, 5, 11, 16, 20). This causes in-
creased resistance to penicillins, cephalosporins, and b-lac-
tam–b-lactamase inhibitor combinations. b-Lactams penetrate
into gram-negative bacteria throughout nonspecific porins
(17). Two major porins have been described in E. coli: OmpF
and OmpC (24). Loss of nonspecific porins in E. coli and other
Enterobacteriaceae are related to increased levels of resistance
to b-lactams, particularly when combined with production of
an efficient b-lactamase(s) (1, 3, 8–10, 13, 21). Zwitterionic
cephalosporins (cefepime, cefpirome, etc.) are more active
against organisms producing increased levels of inducible chro-
mosomal AmpC b-lactamase than are older oxyimino-cepha-
losporins (cefotaxime, ceftriaxone, ceftazidime, etc.) (7). We
have, however, scarce information on the activity of zwitter-
ionic cephalosporins against E. coli hyperproducing AmpC. In
this study, we have evaluated the in vitro activities of imipenem
and cephalosporins against clonally related clinical isolates of
E. coli hyperproducing chromosomal b-lactamase and the pat-
tern of porin expression in these isolates.
Forty-four cefoxitin-resistant (MICs, .32 mg/ml) isolates of
E. coli obtained from clinical samples (January to December
1994) have been studied. Forty isolates were obtained from
inpatients, and four were obtained from outpatients. Identifi-
cation and preliminary susceptibility testing were performed
using commercial panels (panels 6P; Pasco). All 40 isolates
from inpatients showed similar patterns of resistance to b-lac-
tams, fluoroquinolones, co-trimoxazole, and aminoglycosides.
A variety of resistance patterns were observed in isolates from
outpatients, none of them being identical to that of isolates
from inpatients (data not shown). Genomic DNA from the 44
clinical isolates and from strain ATCC 25922 was separated
after digestion with XbaI by pulsed-field gel electrophoresis
(PFGE) as previously described (14). All 40 isolates from in-
patients presented the same PFGE pattern, in contrast to the
4 isolates from outpatients and strain ATCC 25922, which
showed patterns unrelated to each other and to that of isolates
from inpatients (Fig. 1). The activities of cefoxitin (Sigma,
Madrid, Spain), cefotaxime (Sigma), ceftriaxone (Sigma),
ceftazidime (Glaxo, Madrid, Spain), cefepime (Bristol-Myers
Squibb, Madrid, Spain), and imipenem (Merck Sharp and
Dhome, Madrid, Spain) against all 44 isolates were determined
by microdilution (15). MIC ranges and MICs at which 90% of
isolates were inhibited, respectively, for the 40 isolates from
inpatients were as follows (in micrograms per milliliter): .256
and .256 (cefoxitin); 0.5 to 2 and 2 (cefepime), 16 to 128 and
32 (both cefotaxime and ceftriaxone), 32 to 256 and 128
(ceftazidime), and 0.125 to 0.5 and 0.5 (imipenem). All strains
were resistant to cefoxitin and ceftazidime, intermediate or
resistant to cefotaxime and ceftriaxone, and susceptible to both
cefepime and imipenem (15).
Eight isolates from hospitalized patients, including organ-
isms covering the whole range of MICs of ceftazidime and
cefotaxime for the 40 isolates from inpatients, were further
studied. MICs of cephalosporins and imipenem were deter-
mined with Etest strips (AB Biodisk, Solna, Sweden) in the
presence of clavulanic acid (2 mg/ml) or BRL 42715 (4 mg/ml).
A clinical strain of Klebsiella pneumoniae (HUS57/94) produc-
ing SHV-5 b-lactamase (unpublished results) was used as a
control in these studies. MICs of both cefoxitin and cefotaxime
did not decrease in the presence of clavulanic acid. BRL 42715,
however, significantly decreased the MICs of both cefoxitin
and cefotaxime (Table 1). Both b-lactamase inhibitors de-
creased the MIC of cefotaxime, but not of cefoxitin, for K.
pneumoniae HUS57/94 (data not shown).
Plasmid DNA was obtained by the alkaline-lysis method (12)
and analyzed by electrophoresis in 0.7% agarose gels. All eight
isolates contained a plasmid of 5.1 kb; isolate HUS23/94 ad-
ditionally contained a plasmid of 8.0 kb. Attempts to transfer
resistance to cephalosporins from isolates HUS31/94, HUS23/
94, HUS36/94, and HUS47/94 to E. coli J53-2 (F2 pro met Rifr)
by conjugation, transformation (heat shock method), and elec-
troporation, using ampicillin (50 mg/ml), cefoxitin (10 mg/ml),
or cefotaxime (10 mg/ml) as selective agents (22), consistently
failed. Although strains of E. coli producing AmpC-type b-lac-
tamase from plasmid have been described (6), these results
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suggest that the most probable cause of b-lactam resistance in
our isolates is of chromosomal origin.
Isoelectric point (pI) determinations using crude superna-
tants were performed by isoelectric focusing using the Phast-
System (gel pI range, 3.5 to 9; Pharmacia, Sant Cugat del
Vallés, Spain). All eight isolates produced a b-lactamase with
a pI of $9. Isolate HUS23/94 also produced a b-lactamase with
a pI of 5.4, compatible with TEM-1. b-Lactamase activity was
determined spectrophotometrically using crude supernatants
from sonicated cells. One unit of activity was defined as the
amount of enzyme that hydrolyzes 1 mmol of cephaloridine per
min at 37°C. Inhibition of b-lactamase was determined after
preincubation (10 min at 37°C) of supernatants with cloxacillin
(250 mM) or clavulanic acid (2 mM). Cloxacillin and clavulanic
acid inhibited 88.7 to 99.6% and 0.6 to 8.1% of the b-lactamase
activity, except in isolate HUS23/94. Outer membrane protein
profiles from bacteria grown to logarithmic phase in Mueller-
Hinton broth or in nutrient broth were determined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (12% acryl-
amide and 6 M urea in the running gel). OmpF porin was
absent in the eight isolates grown in either Mueller-Hinton
broth or nutrient broth (Fig. 2).
Hyperproduction of AmpC causing resistance of clinical iso-
lates of E. coli to oxyimino-cephalosporins has been previously
documented (2, 4, 16), but the epidemiological relationship of
the strains included in those studies has not been reported. In
this study we have shown that 40 isolates from inpatients were
FIG. 1. PFGE profiles of E. coli clinical isolates hyperproducing chromo-
somal b-lactamase. Lanes 1, 2, 7, and 8: markers. Lanes 3, 4, 5, 6, 9, 10, 11, and
12: isolates HUS4/94, HUS7/94, HUS23/94, HUS31/94, HUS34/94, HUS36/94,
HUS42/94, and HUS47/94, respectively.
TABLE 1. MICs of cephalosporins and cephalosporins plus b-lactamase inhibitorsa
E. coli
isolate




CAZ FOX CTX CAZ FOX FOX-BRL CTX CTX-BRL CLOXc CAd
HUS34/94 32 .256 16 64 .256 24 12 0.25 $9 470 99.6 1.9
HUS47/94 64 .256 16 96 .256 24 16 0.25 $9 215 99.1 7.6
HUS36/94 64 .256 16 24 .256 12 8 0.25 $9 218 99.0 6.3
HUS4/94 64 .256 16 64 .256 16 8 0.25 $9 346 99.1 8.1
HUS23/94 64 .256 32 256e .256 96 48 0.38 $9 1 5.4f 2,057 32.5 31.4
HUS42/94 128 .256 32 64 .256 64 16 0.5 $9 575 99.0 0.6
HUS31/94 128 .256 32 256e .256 24 16 0.25 $9 514 99.0 1.9
HUS7/94 256 .256 128 256e .256 8 24 0.75 $9 394 87.7 2.6
a Abbreviations for cephalosporins: CAZ, ceftzidime; FOX, cefoxitin; CTX, cefotaxime. Abbreviations for b-lactamase inhibitors: CA, clavulanic acid; BRL, BRL
42715. MICs were determined by microdilution or Etest for eight isolates of AmpC-hyperproducing E. coli
b Milliunits of enzyme/milligram of protein.
c Cloxacillin (250 mM).
d Clavulanic acid (2 mM).
e Difficult-to-read end-point.
f Two b-lactamase bands were detected.
FIG. 2. Outer membrane protein profiles of E. coli clinical isolates HUS4/94
(lane 2), HUS7/94 (lane 3), HUS23/94 (lane 4), HUS31/94 (lane 5), HUS34/94
(lane 6), HUS36/94 (lane 7), HUS42/94 (lane 8), and HUS47/94 (lane 9). Lane
1: E. coli JF568 (OmpA1 OmpF1 OmpC1).
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clonally related but epidemiologically unrelated to other
AmpC-hyperproducing strains (data not shown) cultured from
outpatients in the same geographical area. These 40 isolates
presumably represent a single strain causing a nosocomial out-
break. Data on patients from whom the isolates were obtained
are not available for a complete analysis, thus precluding an
adequate epidemiological study.
The isolates described in this report were resistant to oxy-
imino-cephalosporins but susceptible to both cefepime and
imipenem, two compounds highly stable to AmpC b-lacta-
mases from other enterobacteria (7). This study suggests that
both cefepime and imipenem may represent a therapeutic al-
ternative for infections caused by AmpC-hyperproducing E.
coli strains, as suggested for other organisms (23). Loss of both
OmpF and OmpC porins in laboratory mutants of E. coli
determines an 8- to 16-fold increase in the MICs of cephalo-
sporins (9). Loss of OmpF alone in E. coli mutants expressing
increased amounts of AmpC determines a two- to fourfold
increase in the MICs of cephalosporins (10). There is scarce
information on the number and nature of porins expressed by
clinical isolates of E. coli, and the relationship of porin expres-
sion, if any, with antimicrobial resistance. Reguera et al. (21)
reported that seven out of eight clinical strains of E. coli re-
sistant to amoxicillin-clavulanic acid expressed only OmpC or
expressed OmpF with altered electrophoretic mobility. In or-
der to evaluate the role of porins in antimicrobial resistance, it
would be necessary to compare Omp profiles and susceptibility
data of bacteria cultured in the same medium. OmpF, an
important porin for b-lactam penetration (18, 19), is not ex-
pressed in high-osmolarity media, such as Mueller-Hinton
broth, the most commonly used medium for susceptibility test-
ing. In the isolates herein studied, we have observed that
OmpF is not expressed in Mueller-Hinton broth (as would be
expected); nor is it expressed in the low-osmolarity medium
nutrient broth, suggesting that this porin is actually not ex-
pressed by these isolates. This also suggests that resistance due
to cooperation between b-lactamase production and altered
permeability demonstrated in laboratory mutants of E. coli can
also be expressed by clinical isolates.
The level of resistance to cephalosporins varied in different
(but clonally related) isolates. It does not seem probable that
variations in b-lactamase activity accounts for the differences
in susceptibility to cefotaxime and ceftazidime. This is sug-
gested by both the poor correlation between enzyme activity
and MICs (even if strain HUS23/94 is not considered) and by
the differences of MICs of cefoxitin and cefotaxime in the
presence of BRL 42715. It is possible that other mechanisms
(penicillin-binding protein expression, active efflux, etc.) con-
tribute to the observed phenotypes of resistance. New studies
are in progress to evaluate these possibilities.
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